Search
Sulfamerazine
go.drugbank.com/drugs/DB01581ApprovedVet approvedWithdrawnA sulfanilamide that is used as an antibacterial agent.
Ferric cation
go.drugbank.com/drugs/DB13949ApprovedWithdrawnIron deficiency may be characterized without the development of anemia, and may result in functional impairments affecting cognitive development and immunity mechanisms, as well as infant or maternal mortality
Tetracosactide
go.drugbank.com/drugs/DB01284ApprovedInvestigationalTetracosactide exhibits the same activity as natural ACTH with regard to all its biological activities. … Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone.
Aprepitant
go.drugbank.com/drugs/DB00673ApprovedInvestigationalAprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CI NV).
Bile salt-activated lipase
go.drugbank.com/bio_entities/BE0004523TargetEnzymeHumansCatalyzes the hydrolysis of a wide range of substrates including cholesteryl esters, phospholipids, lysophospholipids, di- and tri-acylglycerols, and fatty acid esters of hydroxy fatty acids (FAHFAs) (PubMed:10220579, PubMed:27509211, Pu...
Synonyms: BALEfbemalenograstim alfa
go.drugbank.com/drugs/DB18704ApprovedInvestigationalThis approval was contingent on positive results observed in two pivotal Phase 3 Studies GC-627-04 and GC-627-05 in the US and Europe respectively.[L48887] … [L48852,A262167] As endogenous G-CSF mediates the differentiation of hematopoietic stem cells into granulocytes and eventually neutrophils, the administration of recombinant G-CSF like efbemalenograstim
Hexestrol
go.drugbank.com/drugs/DB07931ApprovedWithdrawnA synthetic estrogen that has been used as a hormonal antineoplastic agent.
Tolcapone
go.drugbank.com/drugs/DB00323ApprovedInvestigationalWithdrawnIt is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa medication. It is a yellow, odorless, non-hygroscopic, crystalline compound.
Voxelotor
go.drugbank.com/drugs/DB14975Approved[L10403] It was developed by Global Blood Therapeutics, Inc. … [T734] Voxelotor was granted accelerated FDA approval on November 25 2019, as it is likely to be a promising treatment for the 100,000 individuals in the U.S. suffering from the disease, in addition